Treats pain of osteoarthritis of the knee(s). ANDA 213040, held by Aurolife Pharma LLC. Diclofenac Sodium.
As of Nov 16, 2026, ANDA 213040 (Diclofenac Sodium), held by Aurolife Pharma LLC, was first approved by FDA on Feb 3, 2023, with 1 approved supplement and 0 published complete response letters.
1. INDICATIONS AND USAGE Diclofenac sodium topical solution is indicated for the treatment of the pain of osteoarthritis of the knee(s). Diclofenac sodium topical solution is a nonsteroidal anti-inflammatory drug
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 3, 2023 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Diclofenac Sodium2% · solution;topical | Diclofenac Sodium | Rx |
| Nov 21, 2024 | Supplement 1Labeling · Standard review | Approved | None posted |
| Feb 3, 2023 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters